Allitinib

Research use only, not for human use.

Allitinib (AST-1306) has anti-cancer activity，and it is an irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively.

Allitinib (AST-1306) has anti-cancer activity，and it is an irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. (In Vitro):AST1306 (AST-1306; 0.19-6.25 μM; 72 hours) inhibit the growth of HIH3T3-EGFR T790M/L858R cells. AST1306 (0.001-1.0 μM; 4 hours) is more than 3000-fold selective for ErbB family kinases over other kinase families. AST1306 inhibits the activation of tyrosine kinases and downstream signaling pathways in A549 cells, Calu-3 cells and SK-OV-3 cells，and dose-dependently and markedly inhibits EGF-induced EGFR phosphorylation in A549 cells.(In Vivo):AST1306 (AST-1306; oral; 25-100 mg/kg) significantly inhibited tumor growth in SK-OV-3 and Calu-3 xenograft models.

AST-1306; ALS 1306

Angiogenesis

EGFR

A1

——

——

897383-62-9

448.9

C24H18ClFN4O2

>98% (HPLC)

——

Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1

——

(-20℃)

With Ice Pack

≥ 2 years